MOUNJARO (Eli Lilly Australia Pty Ltd)
Product name
MOUNJARO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
tirzepatide
Registration type
NCE/NBE
Indication
Type 2 Diabetes Mellitus:
MOUNJARO is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is not tolerated or contraindicated.
- in addition to other medicinal products for the treatment of type 2 diabetes.